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SUMMARY AT A GLANCE 
In combined pulmonary fibrosis and emphysema (CPFE), the likelihood of having 
pulmonary hypertension is explained by the summed baseline CT extents of 
interstitial lung disease and emphysema. There is no synergistic effect In CPFE 
increasing the likelihood of pulmonary hypertension. CPFE is therefore not 
associated with a malignant microvascular phenotype.  
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ABBREVIATION LIST 
CI  confidence interval 
CPFE  combined fibrosis and emphysema  
CPI  composite physiologic index 
CT  computed tomography 
DLco  diffusing capacity for carbon monoxide 
FVC  forced vital capacity 
ILD  interstitial lung disease 
IPF  idiopathic pulmonary fibrosis 
MDT  multi-disciplinary team 
PHT pulmonary hypertension 
RVSP  right ventricular systolic pressure 
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ABSTRACT 
BACKGROUND AND OBJECTIVE: To evaluate whether patients with combined 
pulmonary fibrosis and emphysema (CPFE) have an increased likelihood of 
pulmonary hypertension (PHT) when compared to idiopathic pulmonary fibrosis (IPF) 
patients without emphysema.  
 
METHODS: Two consecutive IPF populations having undergone transthoracic 
echocardiography were examined (n=223 and n=162). Emphysema and interstitial 
lung disease (ILD) extent were quantified visually; ILD extent was also quantified by a 
software tool, CALIPER. Echocardiographic criteria categorised PHT risk. 
 
RESULTS: The prevalence of an increased PHT likelihood was 29% and 31% in each 
CPFE cohort. Survival at 12 months was 60% across both CPFE cohorts with no 
significantly worsened outcome identified when compared to IPF patients without 
emphysema. 
 
Using logistic regression models in both cohorts, total CT disease extent (ILD and 
emphysema) predicted the likelihood of PHT. After adjustment for total disease 
extent, CPFE had no stronger association with PHT likelihood than IPF patients 
without emphysema. 
 
CONCLUSION: Our findings indicate that the reported association between CPFE and 
PHT is explained by the summed baseline CT extents of ILD and emphysema. Once 
baseline severity is taken into account, CPFE is not selectively associated with a 
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malignant microvascular phenotype, when compared to IPF patients without 
emphysema. 
 
KEY WORDS: idiopathic pulmonary fibrosis, computer tomography, emphysema, 
pulmonary hypertension 
 
Short title: PHT likelihood in CPFE 
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INTRODUCTION 
It has now been over 25 years since the initial observation that emphysema co-exists 
in a proportion of patients with idiopathic pulmonary fibrosis (IPF)(1). Over the 
intervening period, the term combined pulmonary fibrosis and emphysema (CPFE)(2) 
has entered the interstitial lung disease (ILD) lexicon to describe a combination of 
two pathologies, namely emphysema and fibrosis, which combine to increase the 
probability of developing of pulmonary hypertension (PHT) when compared to 
patients with IPF alone(3-6). Yet what remains unclear in patients with CPFE is 
whether a symbiotic relationship exists between emphysema and fibrosis where the 
combination of the two disease processes, emphysema and fibrosis, exerts an 
impact greater than the sum of the individual parts on the likelihood of having PHT. 
 
We therefore examined two consecutive populations of IPF patients presenting to 
our institution over a seven-year period. We aimed to identify whether the 
combined severity of emphysema and fibrosis represents a distinct microvascular 
phenotype, with a vasculopathic effect greater than expected from the sum of the 
individual components. 
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METHODS 
Clinical data 
A previously reported consecutive population of 272 patients retrospectively 
diagnosed by a multidisciplinary team (MDT) with IPF from January 2007 to July 2011 
was examined(7). A retrospective review of an ILD database subsequently identified 
201 consecutive patients with an MDT diagnosis of IPF presenting to our institution 
between July 2011 and December 2014. Patients were defined as “ever smokers” 
following evaluation of clinical notes if they had smoked at least one cigarette per 
day for at least one year.  
 
CT and pulmonary function test protocols are included in the supplementary 
appendix S1. Approval for this retrospective study of clinically indicated CT and 
pulmonary function data was obtained from Liverpool Research Ethics Committee 
(Reference: 14/NW/0028), the Institutional Ethics Committee of the Royal Brompton 
Hospital and Mayo Clinic and informed patient consent was not required.  
 
CT evaluation 
CALIPER quantitation of total ILD extent was performed for both cohorts to provide 
an independent measure of ILD extent(8). CALIPER emphysema scores were not 
utilized in the analyses for reasons described in the Supplementary Appendix S1.  
 
CTs were visually scored on a lobar basis with extents of ILD and emphysema 
estimated to the nearest 5%. Visual scoring was performed by two of four 
radiologists: cohort 1 (AN, SLW); cohort 2 (GC, JB). Lobar CT scores for both IPF 
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cohorts were adjusted using normalized lobar volumes with correction factors 
highlighted in Supplementary Table S1. The most disparate 5% (two standard 
deviations) of values were arbitrated by a third scorer (JJ). Discrepancies between 
scorer pairs for the presence of emphysema and emphysema extent in never-
smokers was also consensed by the same third scorer (JJ). 
 
CT total disease extent scores 
Total disease extent on CT at baseline was defined as the sum of ILD extent and total 
visual emphysema extent. Total CT disease extent was used to catergorise patients 
as having an increased echocardiographic likelihood of PHT using two scores: 
1) Sum of CALIPER ILD extent and visual emphysema extent (CILDemph) 
2) Sum of Visual ILD extent and visual emphysema extent (VILDemph) 
 
Definitions of echocardiographic likelihood of PHT 
Only echocardiographic examinations performed within 3 months of the initial 
diagnostic CT scan were considered for analysis. Two definitions of 
echocardiographic likelihood of PHT were considered: 
Increased likelihood of PHT: defined using a threshold of right ventricular systolic 
pressure (RVSP) >50mmHg(9), or two of the following measures: evidence of right 
atrial or ventricular dilatation, evidence of right ventricular dysfunction or a 
pulmonary artery acceleration time <105msec. 
 
High probability of PHT: defined using European Society of Cardiology and European 
Respiratory Society consensus guidelines(10). Patients required a peak tricuspid 
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regurgitation velocity >340m/s, or a peak tricuspid regurgitation velocity >290m/s, 
and two of the following signs: right atrial or ventricular dilatation, evidence of right 
ventricular dysfunction or a pulmonary artery acceleration time <105msec. 
 
Use of the “Increased PHT likelihood” definition allowed evaluation of PHT likelihood 
in patients in whom a tricuspid regurgitation velocity could not be measured. This 
definition also allowed evaluation of PHT likelihood in historic cases, where all the 
various measurements required to satisfy  the 2015 consensus guidelines for a high 
probability of PHT (10), had not been routinely performed. The group of patients 
with a “High likelihood of PHT” included patients with an “Increased probability of 
PHT”(10) that fulfilled the relevant inclusion criteria. As the study evaluated patients 
presenting for their baseline clinical assessment, no study patients had received 
vasodilator medication. 
 
Statistical analysis 
Differences in visual CT scores between scorers were evaluated using the Kappa 
score for categorical variables and the single determination standard deviation for 
continuous variables (Supplementary Table S2). Group differences were examined 
using the Students T-test for continuous variables or the Chi-squared test for 
categorical variables and the Mann Whitney U test for non-normally distributed 
median values. Outcomes were examined using Kaplan Meier survival curves with 
differences between the curves evaluated using the Log Rank test.  
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The relationship between each combined morphologic score (CILDemph and 
VILDemph) and an increased or high likelihood of PHT was explored in separate 
logistic regression models with adjustment made for patient age, gender and 
smoking status (never versus ever). To investigate whether CPFE accords a patient an 
increased likelihood of PHT, beyond that explained by total disease extent on CT 
(CILDemph and VILDemph), a binary emphysema score (presence/absence of 
emphysema) was inserted into each logistic regression model alongside patient age, 
gender, smoking status and either CILDemph or VILDemph. DLco was not used to 
adjust for baseline disease extent in any logistic regression model used to identify 
PHT likelihood. 
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RESULTS 
Baseline parameters 
385/473 (81%) patients across both cohorts had echocardiographic examinations 
within 3 months of the diagnostic CT scan. Baseline characteristics of patients across 
both study cohorts are shown in Supplementary Table S3. The mean interval 
between echocardiography and CT imaging was 8.719.5 days. No significant 
difference in the likelihood of CPFE (p=0.45) or mortality (Log rank test p=0.63) was 
identified between patients that did and did not undergo transthoracic 
echocardiography. Patients that did not undergo echocardiography had less 
extensive disease than patients undergoing transthoracic echocardiography, as 
evidenced by less ILD (scored by both CALIPER and visual analysis), less emphysema, 
a lower CPI score and a higher mean DLco (Supplementary Table S4). In patients that 
did undergo transthoracic echocardiography, emphysema was identified in 171/385 
(44%) patients (Cohort 1 Kappa=0.59; Cohort 2 Kappa=0.45) with a mean 
emphysema extent of 12.2±13.5% in patients with emphysema.  
 
In all analyses in the study, similar results were obtained when both cohorts were 
examined separately. Results for Cohort 1 alone are described in the main 
manuscript, with detailed results for Cohort 2 included in the Supplementary 
Appendix. The final two Results subsections however, represent analyses performed 
on the combined populations of Cohorts 1 and 2. 
 
Amongst patients with CPFE in Cohort 1, the prevalence of an increased likelihood of 
PHT was 27/88 (31%)[Table 1]and the prevalence of a high likelihood of PHT was 
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20/88 (23%). No significant difference in patient age, gender or baseline DLco values 
was identified between IPF and CPFE patients with an increased echocardiographic 
likelihood of PHT (Table 1). The results were maintained in patients with a high 
echocardiographic likelihood of PHT in Cohort 1, and for both PHT definitions in 
Cohort 2 (Supplementary Table S5).  
 
CT features of patients with increased likelihood of PHT  
When patients in Cohort 1 with an increased or high likelihood of PHT were 
examined using the CILDemph and VILDemph scores, CPFE patients were not found 
to have significantly more disease on CT (sum of ILD and emphysema extents) than 
IPF patients (Table 1). In Cohort 2, CPFE patients with an increased and high 
likelihood of PHT had significantly more disease on CT (sum of ILD and emphysema 
extents) when the VILDemph scores were considered but not when using the 
CILDemph score (Supplementary Table 5). When patients with CPFE alone were 
subanalysed, patients with an increased likelihood of PHT had significantly more 
disease on CT than patients without an increased likelihood of PHT: CILDemph 
p=0.0003; VILDemph p=0.02. The results were similar when CPFE patients with and 
without a high likelihood PHT were examined: CILDemph p=0.0003; VILDemph 
p=0.001 (Figure 1; Cohort 2 results are shown in Supplementary Figure 1).  
 
Binary logistic regression models were used to identify variables predictive of an 
increased likelihood of PHT in Cohort 1. Significant associations with an increased 
likelihood of PHT were identified for the combined morphologic scores: CILDemph 
and VILDemph following adjustment for patient age, gender or smoking history 
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(Table 2). Notably, the presence of emphysema (indicating the CPFE phenotype) was 
not independently associated with an increased likelihood of PHT after adjusting for 
baseline total lung disease extent on CT using either combined morphologic score. 
The results did not change when visual emphysema thresholds (>5% and >10%) were 
examined with adjustment made for patient age, gender or smoking history (Table 
2). The results were also maintained when considering CT variables predictive of a 
high likelihood of PHT (Table 2). Results for equivalent analyses in patients in Cohort 
2 are shown in Supplementary Table S6.  
 
To avoid a potential confounding effect on emphysema presence scores following 
model adjustment using patient smoking history, all logistic regression analyses in 
Table 2 and Supplementary Table S6 were repeated with adjustment for patient age 
and gender alone. The results did not change in any of the analyses, when patient 
smoking history was not considered in logistic regression models. 
 
Cohort-wide determinants of PHT likelihood in CPFE patients  
When logistic regression models were applied to CPFE patients in both cohorts, both 
combined morphologic scores predicted an increased likelihood of PHT: 
CILDemph=OR 1.04 CI=1.02-1.06, p<0.0001; VILDemph=OR 1.03 CI=1.01-1.05, 
p=0.0004. Both combined morphologic scores also strongly predicted a high 
likelihood of PHT in CPFE patients: CILDemph=OR 1.05 CI=1.03-1.07, p<0.0001; 
VILDemph=OR 1.05 CI=1.03-1.07, p<0.0001.When patients with severe disease 
(characterized by a baseline DLco<35% predicted) across both cohorts were 
examined together (n=204), CPFE did not independently predict an increased or high 
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likelihood of PHT after adjusting for baseline total lung disease extent on CT using 
either combined morphologic score (Supplementary Table S7).  
 
When ILD extent (scored by either visual analysis or CALIPER) and visual emphysema 
extent were examined in CPFE patients in both Cohorts, ILD and emphysema scores 
had a similar impact on the likelihood of PHT (Table 3). The results were maintained 
when considering criteria representing an increased likelihood of PHT and a high 
likelihood of PHT (Table 3).  
 
Survival in patients with increased likelihood of PHT  
CPFE patients across both Cohorts with an increased echocardiographic likelihood of 
PHT, had a 60% survival at 12 months (Figure 2). No survival difference was 
identified between IPF or CPFE patients with an increased or high likelihood of PHT 
(Figures 2 and 3). Similarly, no survival difference was identified between IPF or CPFE 
patients without an increased or high likelihood of PHT (Figures 2 and 3). 
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DISCUSSION 
Our study has demonstrated that in patients with CPFE, once baseline disease extent 
had been considered (summed CT extents of ILD and emphysema), patients with 
CPFE are no more likely to develop PHT than IPF patients without emphysema. Our 
results were consistent across two separate IPF populations and were maintained 
using two separate definitions of PHT likelihood. Our findings indicate that CPFE 
patients do not express a unique phenotype that predisposes them to pulmonary 
hypertension beyond that expected from the extents of two disease processes, 
namely fibrosis and emphysema. 
 
The CPFE patients with an increased likelihood of PHT in our study demonstrated 
similar baseline DLco characteristics to the studies by Cottin et al(2, 11). Both CPFE 
cohorts in the current study were similar in their CT extents of emphysema and 
prevalence of both increased and high PHT likelihood. Furthermore, both CPFE 
cohorts had an identical 60% 1-year survival when compared to the landmark CPFE 
study examining outcomes in patients with PHT(11). The CPFE population studied by 
Cottin et al(11) had all undergone right heart catheterization and the authors clearly 
acknowledged the potential for a selection bias towards patients at the more severe 
end of the PHT spectrum. The potential for a selection bias in our population-wide 
study of PHT likelihood in IPF patients, was limited by the high proportion of eligible 
patients that received transthoracic echocardiography and the small number of 
patients that therefore could not be analysed. 
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Our CPFE populations had a marginally lower prevalence of increased PHT likelihood 
(29% and 31%) compared to the study of Cottin et al(11) (20/43) 47% which is likely 
to partly reflect the higher threshold for PHT used in our paper (50mmHg versus 
45mmHg) compared to the study of Cottin et al(11). The PHT prevalence in our study 
was markedly lower than that reported by Mejia et al(4) who found that 90% of CPFE 
patients had an RVSP>50mmHg. However the definition of CPFE in the Mejia et al(4) 
study required >10% of the lung to comprise emphysema, and unusually for CPFE 
cohorts, emphysema was positively associated with the extent of fibrosis in their 
study(4). Accordingly, it is probable that the population described by Mejia et al(4) 
represents an outlier subset of patients in whom extensive emphysema coexists with 
extensive fibrosis. 
 
Our analyses have followed a similar strategy to the original description by Cottin et 
al(2). However, because of the accepted limitation of echocardiographic findings in 
an individual patient, instead of diagnosing PHT we have changed our approach to 
express a cohort-wide likelihood of PHT. To this end, we considered functional and 
structural echocardiographic data in 88/105 (84%) CPFE patients in Cohort 1 and 
83/109 (76%) CPFE patients in Cohort 2 which was similar to the proportion of CPFE 
patients undergoing echocardiography in the study by Cottin et al: 43/61 (70%) CPFE 
patients(2).  
 
We considered two definitions for PHT likelihood in our study as our population had 
undergone echocardiography before the release of the 2015 consensus 
guidelines(10). The first definition, namely that of an increased PHT likelihood, 
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enabled categorization of patients with regard to PHT likelihood even if they had not 
undergone measurements included in the new guidelines, but which were not 
always measured in our pre-2015 echocardiographs such as early pulmonary 
diastolic regurgitation velocity and pulmonary artery diameter. The second definition 
of a high PHT likelihood, whilst in line with the current guidelines(10), reduced the 
prevalence of PHT in both cohorts, yet did not change any of our cardinal study 
findings. 
 
Our analyses allow us to interrogate arguments arguing for and against a 
microvascular phenotype in CPFE by examining whether the likelihood of PHT in 
CPFE is primarily linked to the summed extents of ILD and emphysema. As described 
in previous reports, survival in CPFE patients with PHT was curtailed(4, 11). However, 
once baseline extents of fibrosis and emphysema were accounted for, the likelihood 
of PHT did not differ between CPFE patients and IPF patients without emphysema 
suggesting that vasculopathic mechanisms may differ little between CPFE and IPF 
without emphysema. 
 
The perceived limitations of our study may centre on our definition of an increased 
likelihood of PHT based on non-invasive data. In an ideal scenario, all patients would 
have undergone right heart catheterization. However, it is unlikely that such a study 
will ever be performed. We instead chose to evaluate PHT likelihood to avoid 
misleading PHT prevalence statements in our study population. We were obliged to 
rely on cohort wide expressions of PHT likelihood as indicated by the consensus 
European Cardiac Society and European Respiratory Society guidelines(10), and our 
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results remained unchanged across two CPFE cohorts both with the consensus 
criteria (high likelihood of PHT) and using more inclusive echocardiographic criteria 
(increased likelihood of PHT). The two PHT criteria appeared to be equivalent in 
identifying determinants of PHT as judged by extremely similar odds ratios for 
emphysema and fibrosis when CPFE patients in both cohorts were analysed in 
combination (Table 3). 
 
In conclusion, the likelihood of having PHT in CPFE is linked to the summed extents 
of ILD and emphysema. There is no synergistic effect In CPFE increasing the 
likelihood of PHT. Accordingly, with regard to the likelihood of having PHT, CPFE is 
not greater than the sum of its parts (ILD and emphysema) and is not associated with 
a malignant microvascular phenotype. 
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 ELEVATED PHT LIKELIHOOD NO ELEVATED PHT LIKELIHOOD 
 CPFE IPF P value CPFE IPF P value 
Age (years) 67 68 0.60 66 66   0.57 
Gender (M/F) 25/2 41/6 0.48 47/14 61/27   0.30 
Mean FVC (% predicted) 70.3 55.0 0.001 78.7 66.6   0.0002 
Mean DLco (% predicted) 28.0 28.8 0.81 37.5 38.3   0.68 
CILDemph (%) 46.1 40.3 0.21 29.2 25.5   0.18 
VILDemph (%) 66.2 58.4 0.11 52.2 46.6   0.08 
Mean survival (months) 24.1±5.5 27.3±3.5 0.33 34.3±3.1 41.1±3.3   0.15 
Increased likelihood PHT (%) 27/88 (31) 47/135 (35) 0.52      
 
Table 1. Characteristics of CPFE and IPF patients with (left column) and without 
(right column) an “Increased likelihood of PHT” in Cohort 1. The results were 
unchanged when patients with and without a “High likelihood of PHT” were 
examined. Differences were calculated using a Students T-test for continuous 
variables, the Chi-squared test for categorical variables and the Mann Whitney U test 
for medians. Survival differences were calculated using the Log Rank test. 
CILDemph=sum of CALIPER interstitial lung disease extent and visual emphysema 
extent, VILDemph=sum of visual interstitial lung disease extent and visual 
emphysema extent, FVC=forced vital capacity, DLco=diffusion capacity for carbon 
monoxide, PHT=pulmonary hypertension. 
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 Model Variables  Odds 
ratio 
95% Confidence 
Interval 
P value 
Analysis 1 
(Increased 
PHT 
Likelihood) 
Model ia CILDemph 1.05  1.03, 1.07 <0·0001 
 Emphysema >0% 0.62  0.31, 1.26   0.19 
Model ib VILDemph 1.04  1.02, 1.06 <0·0001 
 Emphysema >0% 0.59  0.29, 1.17   0.13 
Analysis 2 
(Increased 
PHT 
Likelihood) 
Model iia CILDemph 1.05  1.03, 1.07 <0·0001 
 Emphysema >5% 0.63  0.27, 1.50   0.30 
Model iib VILDemph 1.04  1.02, 1.06 <0·0001 
 Emphysema >5% 0.59  0.25, 1.41   0.24 
Analysis 3 
(Increased 
PHT 
Likelihood) 
Model iiia CILDemph 1.05  1.03, 1.07 <0·0001 
 Emphysema >10% 0.71  0.26, 1.90   0.49 
Model iiib VILDemph 1.04  1.02, 1.06 <0·0001 
 Emphysema >10% 0.72  0.26, 1.94   0.51 
Analysis 4 
(High PHT 
Likelihood) 
Model ia CILDemph 1.06  1.04, 1.08 <0·0001 
 Emphysema >0% 0.74  0.34, 1.62   0.45 
Model ib VILDemph 1.05  1.03, 1.08 <0·0001 
 Emphysema >0% 0.59  0.27, 1.29   0.19 
Analysis 5 
(High PHT 
Likelihood) 
Model iia CILDemph 1.06  1.04, 1.08 <0·0001 
 Emphysema >5% 0.76  0.30, 1.92   0.56 
Model iib VILDemph 1.06  1.03, 1.08 <0·0001 
 Emphysema >5% 0.53  0.20, 1.43   0.21 
Analysis 6 
(High PHT 
Likelihood) 
Model iiia CILDemph 1.06  1.04, 1.08 <0·0001 
 Emphysema >10% 0.87  0.31, 2.48   0.79 
Model iiib VILDemph 1.05  1.03, 1.08 <0·0001 
 Emphysema >10% 0.68  0.22, 2.06   0.49 
 
Table 2. Variables associated with an increased (Analysis 1-3) and high (Analysis 4-6) 
likelihood of PHT in patients undergoing echocardiography in Cohort 1. In each model, 
logisitic regression was used to demonstrate visual and CALIPER determinants of an 
increased/high likelihood of PHT after correcting for the effects of age, gender and 
smoking status (never vs ever). Two morphological measures of baseline total disease 
severity were analysed. The first represented the combination of visual emphysema 
scores with CALIPER-derived ILD extent: CILDemph (Model a, white) and the second 
represented the combination of visual emphysema scores with visually-derived ILD 
extent: VILDemph (Model b, grey). Emphysema was not associated with PHT, regardless 
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of threshold (>0%=Model i, >5%=Model ii, >10%=Model iii), when adjusting for combined 
ILD and emphysema extents (a and b). The results were maintained when smoking history 
was excluded from all models to ensure the avoidance of any potential confounding with 
emphysema presence scores. PHT = pulmonary hypertension. 
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PHT Likelihood Variables  Odds ratio 95% Confidence 
Interval 
P value 
Increased PHT 
Likelihood 
Visual Emphysema extent 1.03  1.01, 1.06   0·01 
Visual ILD extent  1.03  1.01, 1.05   0.005 
CALIPER ILD extent 1.03  1.01, 1.05   0.002 
High PHT 
Likelihood 
Visual Emphysema extent 1.04  1.01, 1.07   0·003 
Visual ILD extent  1.05  1.03, 1.08 <0.0001 
CALIPER ILD extent 1.03  1.01, 1.06   0.002 
 
Table 3. Logistic regression analyses identifying CT variables associated with an 
increased (white) or high (grey) likelihood of pulmonary hypertension in patients 
with combined fibrosis and emphysema (CPFE). CPFE patients undergoing 
echocardiography in both Cohort 1 and Cohort 2 were combined for the analysis 
(n=171). 
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Figure legends 
 
 
Figure 1. Scatterplots demonstrating the range of total CT disease extent (sum of 
visual emphysema and CALIPER ILD extent) in select patient populations in Cohort 1. 
The left graph (a) separates patients into those with or without an increased 
likelihood of PHT, whilst the right graph (b) separates patients into those with or 
without a high likelihood of PHT. Red bars represent group median values. Column 1 
= IPF patients with an increased/high likelihood of PHT; Column 2 = CPFE patients 
with an increased/high likelihood of PHT; Column 3 = IPF patients without an 
increased/high likelihood of PHT; Column 4 = CPFE patients without an 
increased/high likelihood of PHT. No significant difference in total CT disease extent 
was seen between IPF and CPFE patients with an increased or high likelihood of PHT. 
However total CT disease extent was higher in CPFE patients with an increased or 
high likelihood of PHT compared to patients without an increased/high likelihood of 
PHT. PHT = pulmonary hypertension. 
 
 
 
Figure 2. Kaplan Meier survival curves in for patients across both Cohorts with (a) 
and without (b) an increased likelihood of pulmonary hypertension: combined 
pulmonary fibrosis and emphysema (CPFE)[green], idiopathic pulmonary fibrosis 
(IPF)[blue]. Log rank test=0.99 for patients with an increased likelihood of pulmonary 
hypertension. Log rank test=0.18 for patients without an increased likelihood of 
pulmonary hypertension.    
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Figure 3. Kaplan Meier survival curves for patients across both Cohorts with (a) and 
without (b) a high likelihood of pulmonary hypertension: combined pulmonary 
fibrosis and emphysema (CPFE)[green], idiopathic pulmonary fibrosis (IPF)[blue]. Log 
rank test=0.72 for patients with a high likelihood of pulmonary hypertension. Log 
rank test=0.21 for patients without a high likelihood of pulmonary hypertension.   
 
